NeuroMab™ Anti-OPN BBB Shuttle Antibody(NRZP-1022-ZP2594)

Fig.1 shows an SDS-PAGE analysis of purified MAbs against OPN using antibodies.

Experimental result shows that the cell of S-113-6 antibody treatment significantly reduces than the ability of Mork group (PBS) and the cell migration of irrelevant antibody control group in the 48hrs.

Fig.2 shows specificity differentiation testing of the anti-OPN monoclonal antibodies using an ELISA. Error bar+1 standard error of mean (SEM).

Experimental result shows that the cell of S-113-6 antibody treatment significantly reduces than the ability of Mork group (PBS) and the cell migration of irrelevant antibody control group in the 48hrs.

Fig.3 shows cross-reactivity of MAbs against human and mouse OPN.

The supernatants from the five monoclonal hybridoma (2E11, 2C5 2H9, 1F11 and 2F10) were probed against h-FL OPN and m-FL OPN in (5A) ELISA and in Western blot (5B=human probe and 5C=murine probe).

Fig.4 shows the determination of epitope specifics on the anti-OPN MAbs by ELISA. Antibodies were probed against N-terminal and C-terminal fragments of OPN.

The supernatants from the five monoclonal hybridoma (2E11, 2C5 2H9, 1F11 and 2F10) were probed against h-FL OPN and m-FL OPN in (5A) ELISA and in Western blot (5B=human probe and 5C=murine probe).

Fig.5 shows the characterization of the monoclonal antibodies for neutralization function against OPN-mediated cell adhesion.

The fig shows MAb inhibition of cell adhesion to OPN.